Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Lays Off 34; Deepest Cuts in Early R&D

This story has been corrected from an earlier version that misstated the current number of Genome Therapeutics employees.


NEW YORK, Sept. 25 - Genome Therapeutics will lay off 34 of its staffers in an effort to rein in costs, the company said today. Staff will be culled from early stage R&D and from administrative support, leaving the company with 165 employees.


The move, which is expected to save Genome Therapeutics about $6 million a year, will not affect any of the revenue-producing early-research partnerhips the company has with pharma, according to a company official.


The cuts will instead focus on target-discovery research, sparing Genome Therapeutics' later-stage clinical-research and drug-development efforts.


Genome Therapeutics has a multi-year research alliance with Schering Plough to identify and characterize genes related to asthma. That partnership, scheduled to conclude at the end of 2002, brought the company $33 million through Sept. 29, 2001.

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.